BR112018008708A2 - rsv quimérico, composições imunogênicas e métodos de uso - Google Patents

rsv quimérico, composições imunogênicas e métodos de uso

Info

Publication number
BR112018008708A2
BR112018008708A2 BR112018008708A BR112018008708A BR112018008708A2 BR 112018008708 A2 BR112018008708 A2 BR 112018008708A2 BR 112018008708 A BR112018008708 A BR 112018008708A BR 112018008708 A BR112018008708 A BR 112018008708A BR 112018008708 A2 BR112018008708 A2 BR 112018008708A2
Authority
BR
Brazil
Prior art keywords
immunogenic compositions
methods
chimeric rsv
rsv
respiratory syncytial
Prior art date
Application number
BR112018008708A
Other languages
English (en)
Inventor
ROSTAD Christina
l moore Martin
Original Assignee
Univ Emory
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Emory filed Critical Univ Emory
Publication of BR112018008708A2 publication Critical patent/BR112018008708A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18521—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18561—Methods of inactivation or attenuation
    • C12N2760/18562—Methods of inactivation or attenuation by genetic engineering

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

esta invenção refere-se ao vírus sincicial respiratório (rsv) quimérico, vacina atenuada viva e composições imunogênicas, e modos de uso. em certas modalidades, o vírus sincicial respiratório quimérico tem um padrão de gene mutado codificando uma proteína f de rsv tendo m na posição 79, r na posição 191, k na posição 357 e / ou y na posição 371.
BR112018008708A 2015-10-29 2016-10-27 rsv quimérico, composições imunogênicas e métodos de uso BR112018008708A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562247962P 2015-10-29 2015-10-29
US201662334547P 2016-05-11 2016-05-11
PCT/US2016/058976 WO2017075125A1 (en) 2015-10-29 2016-10-27 Chimeric RSV, Immunogenic Compositions, and Methods of Use

Publications (1)

Publication Number Publication Date
BR112018008708A2 true BR112018008708A2 (pt) 2018-11-06

Family

ID=58630734

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018008708A BR112018008708A2 (pt) 2015-10-29 2016-10-27 rsv quimérico, composições imunogênicas e métodos de uso

Country Status (10)

Country Link
US (2) US11235050B2 (pt)
EP (1) EP3368547A4 (pt)
JP (2) JP7311872B2 (pt)
KR (1) KR20180085730A (pt)
CN (1) CN108602858A (pt)
BR (1) BR112018008708A2 (pt)
CA (1) CA3003726A1 (pt)
MX (1) MX2018005462A (pt)
SG (1) SG11201803581VA (pt)
WO (1) WO2017075125A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10232032B2 (en) 2013-03-14 2019-03-19 Emory University Recombinant RSV with silent mutations, vaccines, and methods related thereto
US9630994B2 (en) 2014-11-03 2017-04-25 University Of Washington Polypeptides for use in self-assembling protein nanostructures
JP7168938B2 (ja) 2017-04-04 2022-11-10 ユニヴァーシティ オブ ワシントン パラミクソウイルスおよび／またはニューモウイルスのｆタンパク質を表示する自己アセンブリするタンパク質ナノ構造およびその使用
CN112088014A (zh) 2018-02-28 2020-12-15 华盛顿大学 自组装纳米结构疫苗
KR20210091749A (ko) * 2018-11-13 2021-07-22 얀센 백신스 앤드 프리벤션 비.브이. 안정화된 융합전 rsv f 단백질
US20220324917A1 (en) * 2021-04-12 2022-10-13 Sk Bioscience Co., Ltd. Recombinant rsv live vaccine strain and the preparing method thereof

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5583024A (en) 1985-12-02 1996-12-10 The Regents Of The University Of California Recombinant expression of Coleoptera luciferase
IL105456A (en) 1992-04-21 1996-12-05 American Home Prod Vaccines of attenuated respiratory syncytial virus
AT401526B (de) 1993-02-10 1996-09-25 Scheirer Winfried Reagenzlösung zur stabilisierung der lumineszenz bei der luciferasemessung
PT702085E (pt) 1994-07-18 2004-04-30 Karl Klaus Conzelmann Virus de arn de cadeia negativa nao segmentada infeccioso recombinante
US7465574B2 (en) 1994-09-30 2008-12-16 Medimmune, Llc Recombinant RSV virus expression systems and vaccines
US7846455B2 (en) 1996-07-15 2010-12-07 The United States Of America As Represented By The Department Of Health And Human Services Attenuated chimeric respiratory syncytial virus
US6689367B1 (en) 1995-09-27 2004-02-10 The United States Of America As Represented By The Department Of Health And Human Services Production of attenuated chimeric respiratory syncytial virus vaccines from cloned nucleotide sequences
US6713066B1 (en) 1996-07-15 2004-03-30 The United States Of America As Represented By The Department Of Health And Human Services Production of attenuated respiratory syncytial virus vaccines involving modification of M2 ORF2
US6923971B2 (en) 1995-09-27 2005-08-02 The United States Of America As Represented By The Department Of Health & Human Services Respiratory syncytial virus vaccines expressing protective antigens from promoter-proximal genes
WO1997012032A1 (en) 1995-09-27 1997-04-03 The Government Of The United States Of America, As Represented By The Department Of Health And Human Services Production of infectious respiratory syncytial virus from cloned nucleotide sequences
US7485440B2 (en) 1995-09-27 2009-02-03 The United States Of America As Represented By The Department Of Health And Human Services Production of attenuated respiratory syncytial virus vaccines involving modification of M2 ORF2
US6214805B1 (en) 1996-02-15 2001-04-10 The United States Of America As Represented By The Department Of Health And Human Services RNase L activators and antisense oligonucleotides effective to treat RSV infections
US6699476B1 (en) 1996-07-15 2004-03-02 Peter L. Collins Production of recombinant respiratory syncytial viruses expressing immune modulatory molecules
CA2257823A1 (en) 1996-07-15 1998-01-22 Government Of The United States Of America As Represented By The Secreta Ry Of The Department Of Health And Human Services National Institutes Of Production of attenuated respiratory syncytial virus vaccines from cloned nucleotide sequences
US5976796A (en) 1996-10-04 1999-11-02 Loma Linda University Construction and expression of renilla luciferase and green fluorescent protein fusion genes
US6074859A (en) 1997-07-08 2000-06-13 Kikkoman Corporation Mutant-type bioluminescent protein, and process for producing the mutant-type bioluminescent protein
US20040005542A1 (en) 2001-06-22 2004-01-08 Krempl Christine D Respiratory syncytial virus vaccines expressing protective antigens from promotor- proximal genes
US20020018780A1 (en) * 2000-05-25 2002-02-14 Scott Koenig Epitope-based vaccine for respiratory syncytial virus F-protein
DE602004027362D1 (de) 2003-03-28 2010-07-08 Medimmune Llc Zusammensetzungen und verfahren mit dem respiratory syncytial virus untergruppe b stamm 9320
HUE032898T2 (hu) 2003-12-24 2017-11-28 De Staat Der Nederlanden Vertegenwoordigd Door De Mini Van Volksgezondheid Welzijn En Sport Légúti óriássejtes vírus transz komplementált genomi hiányossággal
EP3312272B1 (en) 2004-10-08 2019-08-28 The Government of The United States of America as represented by The Secretary of The Department of Health and Human Services Modulation of replicative fitness by using less frequently used synonymous codons
US8772256B2 (en) 2006-11-30 2014-07-08 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Codon modified immunogenic compositions and methods of use
BRPI0809600B1 (pt) 2007-03-30 2023-01-24 The Research Foundation Of State University Of New York Vírus atenuado útil para vacinas
JP5016731B2 (ja) 2008-11-05 2012-09-05 メルク・シャープ・エンド・ドーム・コーポレイション 生弱毒化呼吸器合胞体ウイルス
US10227569B2 (en) 2011-04-12 2019-03-12 Emory University Respiratory syncytial virus expression vectors
ES2651143T3 (es) * 2011-05-13 2018-01-24 Glaxosmithkline Biologicals Sa Antígenos de F de prefusión del VRS
WO2013006797A1 (en) 2011-07-06 2013-01-10 Nanobio Corporation Human respiratory syncytial virus vaccine
US8816081B2 (en) 2012-08-06 2014-08-26 Basf Se Boron containing perylene monoimides, a process for their production, their use as building blocks for the production of perylene monoimide derivatives, monoimide derivatives and their use in dye-sensitized solar cells
CA2900713A1 (en) 2013-02-08 2014-08-14 Steffen Mueller Attenuation of human respiratory syncytial virus by genome scale codon-pair deoptimization
KR102450375B1 (ko) 2013-03-13 2022-10-04 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 선융합(prefusion) RSV F 단백질 및 이의 용도
US9738689B2 (en) * 2013-03-13 2017-08-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Prefusion RSV F proteins and their use
US10232032B2 (en) * 2013-03-14 2019-03-19 Emory University Recombinant RSV with silent mutations, vaccines, and methods related thereto
US9060975B2 (en) * 2013-03-14 2015-06-23 Mucosis Bv Heat-stable respiratory syncytial virus F protein oligomers and their use in immunological compositions

Also Published As

Publication number Publication date
US20180333477A1 (en) 2018-11-22
SG11201803581VA (en) 2018-05-30
KR20180085730A (ko) 2018-07-27
CN108602858A (zh) 2018-09-28
US11235050B2 (en) 2022-02-01
CA3003726A1 (en) 2017-05-04
US20230293660A1 (en) 2023-09-21
EP3368547A1 (en) 2018-09-05
WO2017075125A1 (en) 2017-05-04
EP3368547A4 (en) 2019-06-05
JP7311872B2 (ja) 2023-07-20
JP2023100654A (ja) 2023-07-19
JP2019500320A (ja) 2019-01-10
MX2018005462A (es) 2018-08-01

Similar Documents

Publication Publication Date Title
BR112018008708A2 (pt) rsv quimérico, composições imunogênicas e métodos de uso
CY1121600T1 (el) Σταθεροποιημενα διαλυτα πολυπεπτιδια rsv f προσυντηξης
MX2018002106A (es) Vacunas terapeuticas contra el hpv18.
AR102547A1 (es) Vacunas contra la enfermedad de manos, pies y boca y métodos de fabricación y su uso
MY171210A (en) Stabilized soluble pre-fusion rsv f polypeptides
PH12018000197A1 (en) Hand, foot, and mouth vaccines and methods of manufacture and use thereof
MY169352A (en) Vaccine against rsv
MX2017000394A (es) Vacunas para virus influenza y usos de las mismas.
GB2563524B (en) Long lasting and stable freshening compositions and methods of freshening the air
MX2021010060A (es) Produccion de virus en huevos aviares.
PH12018502332A1 (en) Stabilized pre-fusion rsv f proteins
BR112016016035A2 (pt) gene resistente à praga antropogênica, anticorpo de cadeia única de idiotípico de toxina anti-cry1ab codificado pelo mesmo e aplicação
BR112017004393A2 (pt) formulações de anticorpo
MY198309A (en) Hydroxy methionine analog formulations suibtable for specialty chemical applications
PH12018501154A1 (en) Attenuated infectious bronchitis virus
MX2020011586A (es) Virus vaccinia quimerico sintetico.
PH12020500569A1 (en) Influenza virus vaccines and uses thereof
MX2019002960A (es) Oligonucleótidos modificados y métodos de uso.
EP3939604A3 (en) Influenza hemagglutinin protein vaccines
WO2020061443A3 (en) Methods of making and using universal centralized influenza vaccine genes
BR112019008781A2 (pt) poxvírus quiméricos sintéticos
ZA201800940B (en) Use of il-3, il-33, and il-12p40 for characterization of the respiratory infections by syncytial respiratory virus
MX2018014955A (es) Vacunas atenuadas vivas del virus de la influenza equina.
WO2015050950A3 (en) Influenza hemagglutinin variants and uses therefor
BR112018013400A2 (pt) vacina marcadora de pestivírus

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]